Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | GRK2 | P25098 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151876 | 1.00 | L3MBTL1 (0.63) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL1152714 | 0.99 | L3MBTL1 (0.62) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL9397546 | 0.99 | L3MBTL1 (0.62) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL9397533 | 0.99 | L3MBTL1 (0.62) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL1152712 | 0.99 | L3MBTL1 (0.62) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| SCHEMBL5080341 | 0.99 | L3MBTL1 (0.62) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| SCHEMBL5080346 | 0.99 | L3MBTL1 (0.62) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL9397656 | 0.98 | L3MBTL1 (0.61) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL5079381 | 0.98 | L3MBTL1 (0.61) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL9397472 | 0.98 | L3MBTL1 (0.61) | L3MBTL1HTR1ACYP3A4TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0266574-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-01-05 | — | — | EP | claimed |
| US-5019582-A | Preventing Calcium Overload In Brain Cells | NOVO NORDISK A/S (DK) | 1991-05-28 | — | — | US | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| EP-0339579-B1 | Piperidine compositions and their preparation and use | NOVO NORDISK AS (DK) | 1998-07-15 | — | — | EP | disclosed |
| US-5227379-A | 1-Heterocycyl-4-phenyl substituted, calcium-channel antagonists | NOVO NORDISK A/S (DK) | 1993-07-13 | — | — | US | disclosed |
| US-5208232-A | Anoxia, migraine; antiepileptic and antiischemic agents | NOVO NORDISK A/S (DK) | 1993-05-04 | — | — | US | disclosed |
| US-5158961-A | Treatment of anoxia, migraine, ischemica and epilepsy | NOVO NORDISK A/S (DK) | 1992-10-27 | — | — | US | disclosed |
| US-5017585-A | Piperidine compounds | NOVO NORDISK A/S (DK) | 1991-05-21 | — | — | US | disclosed |
| EP-0374675-A2 | Reduction of piperidine-dion-derivatives and intermediates | NOVO NORDISK A/S (DK) | 1990-06-27 | — | — | EP | disclosed |
| EP-0374674-A2 | Etherification and dealkylation of piperidine derivatives and intermediates | A/S FERROSAN (DK) | 1990-06-27 | — | — | EP | disclosed |
| EP-0339579-A2 | Piperidine compositions and their preparation and use | NOVO NORDISK A/S (DK) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | L3MBTL1 1417/4885HTR1A 4623/4885CYP3A4 4074/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | L3MBTL1 1417/4885HTR1A 4623/4885CYP3A4 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.